医药行业周报:把握结构性机会 优中选优

华鑫证券
Sep 21

1. 创新药出海是产业趋势,把握结构性机会,优中选优根据医药魔方数据,2025年上半年,中国License-out交易共计72笔,已超过2024年全年交易数量的一半;交易总金额较2024年全年高出16%,其中单笔金额超过10亿美元的交易达16笔。重磅交易的落地提升了市场对创新药出海的整体信心,也给与了创新药板块的溢价,医药生物行业指数当期PE(TTM)39.77倍;高于5年历史平均估值31.50倍...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10